Search

Scholarly Works (4 results)

Sort By:

Article
Peer Reviewed

Detection of high-risk human papillomavirus type 16/18 in cutaneous warts in immunocompetent patients, using polymerase chain reaction

Payal, R;
Aggarwal, S Gupta R;
Handa, S;
Radotra, BD;
Arora, SK

Dermatology Online Journal, Volume 12, Issue 6 (2006)

Article
Peer Reviewed

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

Herold, KC;
Gitelman, SE;
Ehlers, MR;
Gottlieb, PA;
Greenbaum, CJ;
Hagopian, W;
Boyle, KD;
Keyes-Elstein, L;
Aggarwal, S;
Phippard, D;
Sayre, PH;
McNamara, J;
Bluestone, JA

UC San Francisco Previously Published Works (2014)

Cover page: Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

Article
Peer Reviewed

Rosiglitazone preserves pulmonary vascular function in lambs with increased pulmonary blood flow

Fineman, Jeffrey;
Oishi, Peter;
Sharma, S;
Datar, SA;
Kumar, S;
Aggarwal, S;
Lu, Q;
Raff, G;
Azakie, A;
Hsu, JH;
Sajti, E

UC San Francisco Previously Published Works (2013)

Pulmonary vascular function is impaired with increased pulmonary blood flow (PBF). We hypothesized that a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist would mitigate this effect.Methods:An aorta-to-pulmonary-artery shunt was placed in 11 f

Detection of high-risk human papillomavirus type 16/18 in cutaneous warts in immunocompetent patients, using polymerase chain reaction

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

Rosiglitazone preserves pulmonary vascular function in lambs with increased pulmonary blood flow

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function